ArticleScientific reports2026
Evaluation of idiopathic olfactory dysfunction as a warning marker for early parkinson's disease: a population-based cross-sectional study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates clinically idiopathic olfactory disorder (IOD) as a potential early marker for Parkinson's disease (PD), using a two-stage screening approach to identify at-risk individuals and enable timely interventions. 1,044 participants aged 18 and older were screened using the Iran Rapid Smell Identification Test (Rapid IR-SIT). After excluding 343 individuals with known causes of OD, 701 participants were assessed for PD risk factors, following the Movement Disorder Society (MDS) guidelines (2015 version). The participants had a mean age of 45.6 years, with 51.3% male participants. While 59.8% scored 6 on the smell test, 25% of those over 50 exhibited IOD, compared to less than 10% in younger individuals. Lower olfactory scores were significantly associated with current smoking (p = 0.001), male sex (p = 0.022), regular pesticide exposure (p = 0.010), non-caffeine use (p = 0.021), and constipation (p = 0.004). Using an 80% probability threshold for prodromal PD, one participant met the criteria, leading to a confirmed early-stage PD diagnosis. These findings highlight the potential of a two-stage screening approach-starting with olfactory testing followed by MDS-based risk assessment - to identify individuals at risk of PD. Although the yield of prodromal cases was low (1/701), this likely reflects stringent IOD criteria and the study's cross-sectional design. The identification of a prodromal PD case underscores the value of olfactory testing in risk stratification, particularly in resource-limited settings. Future longitudinal studies are needed to validate these findings and refine the predictive accuracy of this approach.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.